Trial Profile

A Phase I, Dose Escalation Study Evaluating the Safety, Tolerability and Pharmacokinetics of TAS-115 in Patients with Advanced Solid Tumors

Status: Active, no longer recruiting

Phase of Trial: Phase I

Latest Information Update: 02 Feb 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Pamufetinib (Primary)
Indications Osteosarcoma; Solid tumours
Focus Adverse reactions
Sponsors Taiho Pharmaceutical

Most Recent Events

01 Feb 2022 Planned End Date changed from 31 Dec 2019 to 31 Dec 2022.
12 Jun 2021 Results (at data cut-off 19 Aug 2018; n=20) assessing efficacy and safety of TAS-115 in expansion cohort in osteosarcoma patients, published in the Investigational New Drugs.
10 Dec 2019 Results (n=67; at data cut-off: 19 August 2018) assessing safety, tolerability, pharmacokinetics of TAS-115 in patients with advanced solid tumors, published in the Investigational New Drugs.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com